²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Conditions: Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10; Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Radiation: Total-Body Irradiation Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials